Victoria Dantchenko, MD
Family Medicine · Brooklyn, NYNPI 1811220924
Payments from drug & device makers
Across 125 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$533
- AstraZeneca$502
- GSK$171
- Bayer$169
- Daiichi Sankyo Inc.$124
- Novo Nordisk$100
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,695100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $533 |
| AstraZeneca | 25 | $502 |
| GSK | 7 | $171 |
| Bayer | 7 | $169 |
| Daiichi Sankyo Inc. | 6 | $124 |
| Novo Nordisk | 5 | $100 |
| Lilly USA, LLC | 5 | $92 |
| Exact Sciences | 3 | $88 |
| Pfizer | 4 | $87 |
| Astellas Pharma US Inc | 3 | $81 |
| Amgen | 4 | $74 |
| Boehringer Ingelheim | 4 | $69 |
| Novartis | 3 | $67 |
| Johnson & Johnson(2 entities) | 4 | $67 |
| Dynavax Technologies Corporation | 2 | $62 |
| Amarin Pharma, Inc. | 3 | $56 |
| Cequr Corporation | 1 | $47 |
| Ardelyx, Inc. | 1 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Medtronic | 1 | $26 |
| Shield Therapeutics Inc | 1 | $25 |
| Mayne Pharma Commercial LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Avion Pharmaceuticals | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Althera Pharmaceuticals LLC | 1 | $16 |
| Evofem Biosciences, Inc. | 1 | $11 |
How this compares
$2,695 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 81 | $92,700 |
| TrulicityDulaglutide | 71 | $80,883 |
| OzempicSemaglutide | 53 | $73,610 |
| EliquisApixaban | 62 | $61,734 |
| FarxigaDapagliflozin Propanediol | 34 | $45,607 |
| EntrestoSacubitril/Valsartan | 33 | $31,483 |
| Diclofenac Sodium | 78 | $30,563 |
| MounjaroTirzepatide | 15 | $28,744 |
| LinzessLinaclotide | 15 | $17,094 |
| JanuviaSitagliptin Phosphate | 11 | $16,671 |
| XareltoRivaroxaban | 11 | $16,484 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $14,643 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 51 | $12,380 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $9,654 |
| DuleraMometasone/Formoterol | 17 | $8,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $92 | $109,62786 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $69 | $100,44896 claims |
| Novo NordiskOzempic | $100 | $73,61053 claims |
| PfizerEliquis | $87 | $61,73462 claims |
| AstraZenecaFarxiga, Symbicort | $502 | $53,58768 claims |
| NovartisEntresto | $67 | $31,48333 claims |
| AbbVieLinzess, Lumigan, Synthroid | $533 | $21,44739 claims |
| Johnson & JohnsonXarelto | $67 | $16,48411 claims |
| GSKIncruse Ellipta | $171 | $9,65423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Brooklyn
- Michael YuryevBrooklyn$589K
- Matthew SpitzerBrooklyn$469K
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.